[go: up one dir, main page]

AU2001234690A1 - 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa - Google Patents

2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa

Info

Publication number
AU2001234690A1
AU2001234690A1 AU2001234690A AU3469001A AU2001234690A1 AU 2001234690 A1 AU2001234690 A1 AU 2001234690A1 AU 2001234690 A AU2001234690 A AU 2001234690A AU 3469001 A AU3469001 A AU 3469001A AU 2001234690 A1 AU2001234690 A1 AU 2001234690A1
Authority
AU
Australia
Prior art keywords
quinoxalone
quinolone
inhibitors
factor
quinoxalone inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001234690A
Other languages
English (en)
Inventor
Robert Scarborough
Bing-Yan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR Therapeutics Inc filed Critical COR Therapeutics Inc
Publication of AU2001234690A1 publication Critical patent/AU2001234690A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001234690A 2000-02-01 2001-02-01 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa Abandoned AU2001234690A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17938900P 2000-02-01 2000-02-01
US60179389 2000-02-01
US19172200P 2000-03-24 2000-03-24
US60191722 2000-03-24
PCT/US2001/003176 WO2001057021A2 (fr) 2000-02-01 2001-02-01 2-[1H]-QUINOLONE ET 2-[1H]-QUINOXALONE INHIBITEURS DU FACTEUR Xa

Publications (1)

Publication Number Publication Date
AU2001234690A1 true AU2001234690A1 (en) 2001-08-14

Family

ID=26875280

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001234690A Abandoned AU2001234690A1 (en) 2000-02-01 2001-02-01 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa

Country Status (4)

Country Link
US (1) US6777413B2 (fr)
EP (1) EP1255741A2 (fr)
AU (1) AU2001234690A1 (fr)
WO (1) WO2001057021A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962926B2 (en) 2001-01-31 2005-11-08 Telik, Inc. Antagonist of MCP-1 function, and compositions and methods of use thereof
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
TWI245761B (en) 2001-03-01 2005-12-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
US6677365B2 (en) 2001-04-03 2004-01-13 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
WO2004050637A2 (fr) 2002-12-03 2004-06-17 Axys Pharmaceuticals, Inc. Derives de 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine utilises en tant qu'inhibiteurs du facteur viia
AU2006244072B2 (en) 2005-05-10 2012-09-20 Intermune, Inc. Pyridone derivatives for modulating stress-activated protein kinase system
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
WO2009021965A2 (fr) 2007-08-15 2009-02-19 Glaxo Group Limited Composés
HRP20120328T2 (hr) 2007-11-15 2012-09-30 Gilead Sciences Inhibitori replikacije virusa humane imunodeficijencije
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
EP2296653B1 (fr) 2008-06-03 2016-01-27 Intermune, Inc. Composés et procédés de traitement des troubles inflammatoires et fibrotiques
LT2841428T (lt) 2012-04-24 2018-12-10 Vertex Pharmaceuticals Incorporated Dnr-pk inhibitoriai
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN105246883B (zh) 2013-03-12 2017-07-21 沃泰克斯药物股份有限公司 Dna‑pk抑制剂
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
WO2016015597A1 (fr) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Composés utilisés comme petits molécules inhibitrices de cdk et leurs utilisations
MA40551A (fr) 2014-08-01 2021-04-07 Nuevolution As Composés actifs envers des bromodomaines
TW201711999A (zh) 2015-09-03 2017-04-01 佛瑪治療公司 ﹝６，６﹞稠合雙環組蛋白脫乙醯基酶８（ｈｄａｃ８）抑制劑
TW201815418A (zh) 2016-09-27 2018-05-01 Vertex Pharma 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475009A (en) * 1994-09-12 1995-12-12 Abbott Laboratories 1, 2-dialkoxyethanes as 5-lipoxygenase inhibitors
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
AU2074699A (en) 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
IL137655A0 (en) * 1998-03-31 2001-10-31 Warner Lambert Co Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
NZ506985A (en) 1998-03-31 2003-10-31 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors
IL147317A0 (en) 1999-07-16 2002-08-14 Bristol Myers Squibb Pharma Co NITROGEN CONTAINING HETEROBICYCLES AS FACTOR Xa INHIBITORS
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa

Also Published As

Publication number Publication date
US6777413B2 (en) 2004-08-17
EP1255741A2 (fr) 2002-11-13
US20020058657A1 (en) 2002-05-16
WO2001057021A2 (fr) 2001-08-09
WO2001057021A3 (fr) 2002-02-14

Similar Documents

Publication Publication Date Title
AU2001234690A1 (en) 2-(1h)-quinolone and 2-(1h)-quinoxalone inhibitors of factor xa
AU2001249399A1 (en) Isoquinolone inhibitors of factor xa
AU2002214626A1 (en) Quaternary amines and related inhibitors of factor xa
AU6762400A (en) Inhibitors of factor xa
AU2001240542A1 (en) Heterocyclic compounds and their use as parp inhibitors
AU4166400A (en) Alkenyl and alkynyl compounds as inhibitors of factor xa
AU2001234705A1 (en) Indalone and benzimidazolone inhibitors of factor xa
HUP0203289A3 (en) Benzamides and related inhibitors of factor xa
AU2001236605A1 (en) Indole and benzimidazole inhibitors of factor xa
ZA200306488B (en) Benzamides and related inhibitors of factor Xa.
AU2003301662A1 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
AU2002356762A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
AU2002254328A1 (en) Inhibitors and disassemblers of fibrillogenesis
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001249397A1 (en) Oxindole inhibitors of factor xa
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2001297648A1 (en) Substituted carboxamides as inhibitors of factor xa
AU2002256085A1 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
AU2002216649A1 (en) Benzoxazole lpaat- beta inhibitors and uses thereof
AU2002306624A1 (en) Heterocyclic analgesic compounds and methods of use thereof
AU2002303264A1 (en) Fused heterocyclic inhibitors of factor xa
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2001294824A1 (en) Piperazine based inhibitors of factor xa
AU2003251047A1 (en) Use of quinoline derivatives with anti-integrase effect and applications thereof